Pipequaline is primarily researched for its potential applications in the field of neuroscience and psychiatry. It has been studied for its anxiolytic properties, showing promise in reducing anxiety without the sedative effects commonly associated with other anxiolytic drugs. This makes it a candidate for developing treatments for anxiety disorders. Additionally, its interaction with GABA receptors suggests potential use in managing conditions related to neurotransmitter imbalances, such as certain types of epilepsy or insomnia. Research is ongoing to explore its efficacy and safety in these therapeutic areas.